Epigral Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹746 Cr +27.1% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
E

Epigral Ltd

Q4 FY26Chemicals & Petrochemicals

Epigral Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹736Cr
+17.2% YoY
+23.3% QoQ
Net profit
₹82Cr
−5.7% YoY
+110.3% QoQ
Margin
23%
−5 pp YoY
+6 pp QoQ
Price₹1,126
Market cap₹4.8K Cr
P/E17.8

The short version

The company targets a volume growth of around 10% to 12% for FY27. Epigral targets a volume growth of around 10% to 12% for FY27, driven by capacity expansions in higher value products like CPVC and ECH.

From Epigral Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company targets a volume growth of around 10% to 12% for FY27.
  • Revenue growth is expected to improve over FY26, with FY27 anticipated to be better than FY26 in terms of volume and value growth.
  • Capacity additions, especially commissioning of CPVC and Epichlorohydrin (ECH) units, are on track and expected to support growth.
  • Gradual ramp-up to optimum utilization levels by FY28 is planned (CPVC approximately 75%, ECH around 80%).
  • Chlorotoluene product line is expected to contribute sizably in FY27, with volume ramp-up continuing.

2 more points from Epigral Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Epigral Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Epigral is commissioning capacity expansion projects for Epichlorohydrin (ECH) and CPVC in Q2 FY27, expected to ramp up gradually and reach optimum utilization (CPVC ~75%, ECH ~80%) by FY28.
  • They are working on a new greenfield project; site evaluation and due diligence are ongoing with plans to announce the project within the current year to sustain post-FY29 growth.
  • No immediate plans to expand caustic soda capacity, but future capacity increase possible if required.
  • The company follows a cautious, step-by-step capex approach, announcing new projects as existing ones near completion.

2 more points from Epigral Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Epigral Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights related to demand and volumes include: - Chlorotoluene had a slow start in FY26 due to approvals/testing; significant volume pickup expected in FY27 with utilization around 40%. - Demand is expected to improve gradually from May onwards after some recent uncertainties due to global geopolitical tensions. - There is a volume growth expectation of around 10-12% in FY27, driven by normalizing demand conditions and capacity expansions.

2 more points from Epigral Ltd's call on order book

Create a free account to keep reading this call

Epigral Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Epigral Ltd Q4 FY26 results — key figures

Epigral Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue736628+17.2%597+23.3%
Operating profit (EBITDA)169173-2.3%103+64.1%
Operating margin23%28%-5 pp17%+6 pp
Profit before tax111131-15.3%55+101.8%
Net profit (PAT)8287-5.7%39+110.3%
EPS (₹)18.9920.08-5.4%9.07+109.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹64 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Indian Phosphate (Q4 FY26)

    H2 FY26 Revenue (Consolidated):** ₹580.25 Cr, up from ₹451.59 Cr in H2 FY25 — a year-on-year increase of ₹128.66 Cr. Key investor presentation takeaways from In

  • Paragon Fine (Q4 FY26)

    Revenue for H2FY26:** Rs 68.88 Cr, up 7.41% YoY from Rs 64.13 Cr in H2FY25 (Page 22). Key investor presentation takeaways from Paragon Fine's Q4 FY26 investor p

  • IVP (Q4 FY26)

    Q4 FY26 revenue from operations: ₹164.44 crore . Key investor presentation takeaways from IVP's Q4 FY26 investor presentation — and how it ranks against sector

  • Vishnu Chemicals (Q4 FY26)

    Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Epigral Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Epigral Ltd Q4 FY26 results?

The company targets a volume growth of around 10% to 12% for FY27. Epigral targets a volume growth of around 10% to 12% for FY27, driven by capacity expansions in higher value products like CPVC and ECH.

What is Epigral Ltd share price analysis?

Epigral Ltd currently shows a neutral. The stock trades at a P/E of 17.8 with a market cap of ₹4,828 Cr. Investors should review the full earnings analysis for detailed insights.

Is Epigral Ltd planning capital expenditure?

Epigral is commissioning capacity expansion projects for Epichlorohydrin (ECH) and CPVC in Q2 FY27, expected to ramp up gradually and reach optimum utilization (CPVC ~75%, ECH ~80%) by FY28.

Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.